Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Rhea-AI Summary

Metsera (NASDAQ: MTSR) will present new research on its obesity treatment portfolio at the 85th Scientific Sessions of the American Diabetes Association. The presentations will focus on MET-097i, their lead monthly GLP-1 receptor agonist, featuring clinical data from its Phase 1/2 trial including body weight changes and tolerability data after twelve weekly doses and a single monthly dose. The company will also present preclinical data on MET-233i, their monthly ultra-long acting amylin analog. The scientific sessions will include a total of eight presentations covering clinical trials, preclinical research, and health economics studies. The research showcases Metsera's development of next-generation approaches for treating overweight and obesity through ultra-long acting, scalable, and combinable therapies.

Positive

• Company has multiple drug candidates in development for obesity treatment
• Lead drug MET-097i has completed Phase 1/2 clinical trial
• Portfolio includes innovative monthly dosing formulations
• Comprehensive research program with 8 presentations at major scientific conference

Negative

• None.

Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations

Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly, ultra-long acting amylin analog

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its portfolio of ultra-long acting, scalable, and combinable therapies, including updated clinical and preclinical findings from lead program MET-097i, at the 85^th Scientific Sessions of the American Diabetes Association® (ADA).

“We look forward to presenting work spanning our portfolio to the scientific community at this year’s ADA meeting,” said Whit Bernard, Chief Executive Officer of Metsera. “Our presentations, including clinical data from the completed Phase 1/2 trial of MET-097i and preclinical findings for our other programs, showcase the breadth of our next-generation approaches to address the need for scalable and differentiated treatments for overweight and obesity.”

Presentation Highlights

MET-097i: A fully biased, ultra-long acting GLP-1 receptor agonist

MET-097i is Metsera’s fully biased, monthly, ultra-long acting GLP-1 receptor agonist. Metsera will present clinical data from MET-097i’s Phase 1/2 clinical trial in two presentations, including change in body weight and tolerability data after twelve weekly doses and after a single candidate monthly dose.

MET-233i: An ultra-long acting amylin analog

MET-233i is Metsera’s monthly, ultra-long acting amylin analog. Metsera will present preclinical data, including detailed pharmacokinetic and change in body weight data.

Presentation Details:

MET-097i: A fully biased ultra-long acting GLP-1 receptor agonist

Clinical data

• Title: A Twelve-Week Trial of MET-097—A Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (788-P)
  Session: Sunday General Poster Session
  Presenter: Robert Stoekenbroek, M.D., Ph.D., Head of Portfolio Strategy at Metsera
  Time/Date: Sunday, June 22; 12:30-1:30pm CDT
  Location: Poster Hall (Hall F1), 122

• Title: Safety, Tolerability, PK, and Efficacy of MET-097—A Next-Generation Nutrient-Stimulated Hormone Peptide Analog for Chronic Weight Management (753-P)
  Session: Sunday General Poster Session
  Presenter: Steve Marso, M.D., Chief Medical Officer at Metsera
  Time/Date: Sunday, June 22; 12:30-1:30pm CDT
  Location: Poster Hall (Hall F1), 088

Preclinical data

• Title: MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (794-P)
  Session: Sunday General Poster Session
  Presenter: Charlotte Hinds, Ph.D., Senior Director, Research & Development at Metsera
  Time/Date: Sunday, June 22; 12:30-1:30pm CDT
  Location: Poster Hall (Hall F1), 128

• Title: Cellular Characterisation of Signalling and Receptor Trafficking Induced by MET-097, a G Protein-Biased GLP-1R Agonist (799-P)
  Session: Sunday General Poster Session
  Presenter: Billy Peter Baxter, Ph.D., Imperial College London
  Time/Date: Sunday, June 22; 12:30-1:30pm CDT
  Location: Poster Hall (Hall F1), 133

MET-233: An ultra-long acting amylin analog

Preclinical data

• Title: MET-233 Is an Ultra-Long-Acting Amylin Receptor Agonist (894-P)
  Session: Sunday General Poster Session
  Presenter: James S Minnion, Ph.D., Vice President, Research & Development at Metsera
  Time/Date: Sunday, June 22; 12:30-1:30pm CDT
  Location: Poster Hall (Hall F1), 190

Pipeline programs

Preclinical data

• Title: Therapeutic NuSH Cocktails—Coadministration of Ultra-Long-Acting GLP-1, GIP, Glucagon, and Amylin Peptide Analogs Induce Profound Weight Loss in DIO Mice (765-P)
  Session: Sunday General Poster Session
  Presenter: Robert Hansford, Ph.D., Preclinical Research Scientist at Metsera
  Time/Date: Sunday, June 22; 12:30-1:30pm CDT
  Location: Poster Hall (Hall F1), 100

Health Economics and Outcomes Research

• Title: Titration to Maintenance Doses of GLP-1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real-World Claims Dataset (758-P)
  Session: Sunday General Poster Session
  Presenter: Shannon Armstrong, Vice President, Global Value and Access at Metsera
  Time/Date: Sunday, June 22; 12:30-1:30pm CDT
  Location: Poster Hall (Hall F1), 093

For more information about Metsera’s presence at ADA, visit https://metsera.com/ada/.

About Metsera

Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at www.metsera.com and follow us on LinkedIn and X.

Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at investors.metsera.com. In addition, you may sign up to automatically receive email alerts and other information about the Company by using the “Email Alerts” option on the Investors & Media page and submitting your email address.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Examples of such statements include, but are not limited to, statements relating to Metsera's expectations regarding participation and presentations at the 85^th Scientific Sessions of the American Diabetes Association® (ADA), its research and development activities, and statements regarding the efficacy, safety and potential regulatory progress of its investigational candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Metsera’s business outlined in Metsera’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of its Annual Report on Form 10-K for the year ended December 31, 2024. Forward-looking statements are not guarantees of future performance, and Metsera’s actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Metsera makes in this press release speak only as of the date of this press release. Metsera assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:
Jono Emmett
Metsera
media@metsera.com

FAQ

What is Metsera's lead drug candidate for obesity treatment?

Metsera's lead drug candidate is MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist currently in clinical development.

How many presentations will Metsera (MTSR) deliver at the ADA Scientific Sessions?

Metsera will deliver eight presentations at the ADA Scientific Sessions, including clinical data from MET-097i's Phase 1/2 trial and preclinical data from other programs.

What are the key drug candidates in Metsera's obesity portfolio?

Metsera's key drug candidates include MET-097i (a monthly GLP-1 receptor agonist) and MET-233i (a monthly ultra-long acting amylin analog).

What phase of development is Metsera's MET-097i currently in?

MET-097i has completed a Phase 1/2 clinical trial, with data to be presented at the ADA Scientific Sessions.

What differentiates Metsera's obesity treatments from others?

Metsera's treatments are designed to be ultra-long acting with monthly dosing, scalable, and combinable, offering next-generation approaches to obesity treatment.